Yumei Shi
Tao Liang1
Chao Shi
Jun Zhang- 1Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China
- 2The Neurological Disease Diagnosis and Treatment Center, Third People’s Hospital Affiliated to Zunyi Medical University, Zunyi, China
Bacterial meningitis represents a devastating inflammatory disease of the central nervous system (CNS), characterized by the invasion of pathogens across the blood-brain barrier (BBB) and subsequent dysregulated immune responses. Key inflammatory mechanisms include pathogen recognition by microglial TLRs and NLRP3, neutrophil infiltration, and cytokine storms such as IL-1β and TNF-α, leading to BBB disruption, cerebral edema, and neuronal injury. Despite antimicrobial therapy, excessive inflammation often results in neurological sequelae. Emerging strategies target immunomodulation through inflammasome inhibitors and BBB preservation using nanoparticle drug delivery to mitigate inflammation-driven CNS damage. This review focuses on the intricate interplay between bacterial virulence factors and neuroinflammatory cascades, with particular emphasis on Streptococcus pneumoniae as a model pathogen. By integrating recent advances in molecular pathogenesis and translational immunology, this review provides a framework for developing precision therapies to mitigate inflammation-mediated CNS damage in bacterial meningitis.
1 Introduction
Bacterial meningitis is a severe CNS infection defined by purulent inflammation and pathogen detection in cerebrospinal fluid (CSF) (1, 2). Streptococcus pneumoniae, the leading cause, penetrates the blood–brain barrier (BBB) via hematogenous spread, triggering acute meningeal inflammation, with mortality rates up to 30% and long-term neurological sequelae in 50% of survivors (3). Additional pathogens, including Neisseria meningitidis, group B Streptococcus, and Streptococcus suis, contribute to its clinical heterogeneity (4, 5). Upon CNS entry, microbial toxins and an exacerbated host immune response elicit secondary brain injury, including ischemia, intracranial hypertension, and hydrocephalus (6). Concurrently, pathogen-derived toxins and dysregulated host immune responses exacerbate cerebral injury, culminating in pathological cascades such as cerebral ischemia, intracranial hypertension, and hydrocephalus (7). These processes ultimately result in irreversible neurological sequelae in over half of cured patients (8, 9).
Despite advancements in antimicrobial therapy, global morbidity and mortality remain unacceptably high, necessitating deeper mechanistic insights to overcome current therapeutic limitations (10). The dynamic molecular mechanisms underlying BBB disruption in pneumococcal meningitis and their correlation with neurological sequelae remain incompletely elucidated. Notably, the spatiotemporal regulation of pathogen-host interaction networks, particularly those involving signaling pathways governing BBB permeability, demands systematic exploration (11, 12). This review synthesizes current knowledge on the molecular mechanisms by which Streptococcus species compromise the BBB, with emphasis on the pathological cascades driving bacterial meningitis. By delineating these processes, we aim to provide a theoretical foundation for novel therapeutic strategies targeting BBB preservation, thereby improving clinical outcomes in patients afflicted by this devastating disease.
2 Acute pneumococcal meningitis and the BBB
2.1 Physiological structure and function of the BBB
The BBB represents a sophisticated neurovascular unit comprising specialized cerebral microvascular endothelial cells that interact bidirectionally with astrocytes, pericytes, and the extracellular matrix to establish and maintain central nervous system homeostasis through highly regulated tight junction complexes and coordinated intercellular signaling pathways (13, 14). Structurally, it consists of cerebral microvascular endothelial cells forming tight junctions, composed of transmembrane proteins and cytoplasmic anchors (zonula occludens), that restrict >99% of blood-borne pathogens while allowing regulated paracellular transport through junctional adhesion molecules (15, 16). The maintenance of BBB integrity depends on coordinated multicellular interactions where pericytes modulate angiogenesis through PDGFR-β signaling (17, 18), astrocytes secrete laminins to stabilize endothelial polarity (19, 20), and microglia maintain equilibrium between pro- and anti-inflammatory responses (21, 22). Physiological immune surveillance occurs through meningeal lymphatic drainage of cerebrospinal fluid components, including memory T cells (23, 24). Functionally, it operates through the physical exclusion of pathogens and inflammatory cells, alongside selective nutrient and waste transport, as well as immunomodulation by perivascular macrophages and endothelial pattern recognition receptors, which collectively prevent excessive inflammation (25, 26). In pneumococcal meningitis, pathogen virulence factors disrupt these mechanisms, collapsing CNS immune privilege and causing irreversible neurological damage.
2.2 Pneumococcal transmigration across the BBB into the CNS
Nasopharyngeal colonization by Streptococcus pneumoniae initiates pneumococcal meningitis pathogenesis (12, 27). Following mucosal breach, the pathogen spreads hematogenously through three main routes: middle ear invasion via the eustachian tube, alveolar dissemination, or direct vascular penetration causing bacteremia (28). Once in the bloodstream, pneumococcal virulence factors, including adhesins and cytolytic toxins (pneumolysin), disrupt the BBB by promoting endothelial cell adhesion, tight junction breakdown, and activation of inflammatory pathways. This cascade enhances BBB permeability, facilitating bacterial migration into the CNS (29). The interaction between bacterial effectors and host immune responses, alongside BBB reprogramming, forms the foundation for intracranial invasion (12, 29).
2.2.1 Pneumococcal capsule in CNS invasion
Streptococcus pneumoniae employs the polysaccharide capsule as a key virulence factor for CNS invasion (30). The capsule’s dense structure sterically hinders complement deposition and phagocytic clearance, with encapsulated strains showing greater resistance to serum killing and neutrophil phagocytosis than unencapsulated variants (31). Paradoxically, while the capsule masks surface adhesins such as PspA/PspC, reducing mucosal colonization efficiency, S. pneumoniae dynamically regulates capsule expression via quorum sensing. During mucosal colonization, low-capsule phenotypes expose adhesins, whereas hematogenous dissemination triggers high-capsule expression for immune evasion (31–33). Pneumococcal surface proteins (Psps) orchestrate the pathogen’s triphasic invasion cascade spanning nasopharyngeal mucosa, bloodstream, and BBB through multimodal adhesion mechanisms. The pilus-associated adhesin RrgA mediates endothelial anchoring by specifically recognizing host polyimmunoglobulin receptor (plgR) and PECAM-1, establishing a molecular foothold for BBB breaching (34). Neuraminidase A synergistically enhances endothelial binding efficacy by targeting protein G-like lectin domains on the endothelium, with histopathological studies confirming that preferential adhesion of S. pneumoniae to subarachnoid vascular endothelia initiates CNS invasion, followed by dissemination along cortical and choroid plexus endothelial cells (35). The choline-binding protein (Cbp) family, which anchors to host cells via phosphorylcholine moieties, plays dual immunomodulatory and barrier-penetrating roles in pneumococcal pathogenesis. Specifically, PspC promotes endothelial adhesion through interaction with the polymeric immunoglobulin receptor (plgR), whereas CbpA facilitates transcytosis by engaging the platelet-activating factor receptor (PAFR) (29, 36). Concurrently, PLA2 acts as a critical inflammatory amplifier by hydrolyzing membrane phospholipids to generate arachidonic acid precursors. This process drives the aberrant upregulation of endothelial adhesion molecules, thereby exacerbating neuroinflammation. Notably, elevated plasma PLA2 levels exhibit a positive correlation with disease severity in pneumococcal meningitis, supporting its utility as a biomarker for monitoring neuroinflammatory progression (37).
2.2.2 Dual mechanisms of pneumolysin in BBB disruption and neuroinflammation
Pneumolysin (Ply) is a cholesterol-dependent, pore-forming toxin that contributes to BBB disruption through both direct cytotoxicity and immunomodulatory effects (38, 39). It forms transmembrane pores approximately 19–30 nm in diameter via its β-barrel domain, resulting in the collapse of ion gradients and subsequent lytic cell death (40). Mechanistically, Ply exerts direct cytotoxic effects by disrupting (41, 42) in cerebral microvascular endothelial cells, inducing retraction of astrocytic end-feet, and triggering pyroptosis in microglia, all of which collectively compromise BBB integrity (43). In parallel, Ply modulates host inflammatory signaling by dose-dependently activating the NLRP3 inflammasome, thereby promoting the maturation of IL-1β and IL-18. It also stimulates the TLR4/NF-κB signaling axis, leading to increased production of chemokines such as CXCL8 and CCL2, which facilitate neutrophil transendothelial migration and amplify neuroinflammatory cascades (44). Notably, Ply concentrations activate membrane repair mechanisms, fostering an immunosuppressive microenvironment through IL-10 secretion and TLR2 signaling inhibition, enabling bacterial immune evasion. This dysregulation of pro-/anti-inflammatory equilibrium underpins tissue damage and pathogen dissemination in pneumococcal meningitis (45, 46). Furthermore, Ply exacerbates CNS microenvironmental imbalance by impairing meningeal ciliary clearance, collapsing neuronal mitochondrial membrane potential, and inducing astrocytic cytoskeletal disorganization, collectively driving irreversible neurological deficits (47–49).
2.3 Role of host inflammatory responses in determining outcomes of pneumococcal meningitis
2.3.1 Brain microvascular endothelial cells
Brain microvascular endothelial cells (BMECs) form the structural core of the BBB, providing a frontline defense against hematogenous pathogens such as Streptococcus pneumoniae and S. suis. These cells establish high transendothelial resistance via tight (occludin, claudin-5, ZO-1) and adherens (VE-cadherin) junctions (50). During streptococcal meningitis, BMECs undergo pathogenic reprogramming in response to microbial adhesins, pore-forming toxins, and systemic inflammation (51). Through pattern recognition receptors (TLR2, TLR4, NOD-like receptors), BMECs detect pathogen-associated molecular patterns (PAMPs) like lipoteichoic acid, pneumolysin, and suilysin. Activation of TLR2/4–MyD88 signaling upregulates proinflammatory cytokines (IL-1β, TNF-α), chemokines (CXCL8, CCL2), and adhesion molecules (ICAM-1, VCAM-1), facilitating leukocyte recruitment (52, 53). In addition, streptococcal virulence factors exert direct cytotoxic effects on BMECs. Pneumolysin disrupts ion gradients and triggers necroptosis or pyroptosis via β-barrel pore formation; suilysin induces Ca²+-dependent calpain activation, destabilizing cytoskeletal integrity (51). Histological analyses reveal endothelial swelling, junctional disassembly, and actin collapse, enhancing BBB permeability (3). BMECs also shape CNS immunity by secreting IL-6, TNF-α, and CXCL10, promoting Th1 polarization and microglial activation. Moreover, NLRP3 inflammasome activation in BMECs—via toxin-induced K+ efflux and mitochondrial stress—leads to IL-1β/IL-18 maturation and pyroptosis (54). Thus, BMECs function not only as structural barriers but as immunologic sentinels central to CNS invasion and neuroinflammation.
2.3.2 Microglia
The pathogenesis of streptococcal meningitis involves a complex interplay between microbial virulence factors and coordinated responses from the neurovascular unit components. Microglia, as the CNS’s primary immunoregulatory cells, initiate the inflammatory cascade through pattern recognition receptors such as TLR2, TLR4, andNLPR3. These receptors specifically detect pneumococcal pathogen-associated molecular patterns including pneumolysin, lipoteichoic acid, and peptidoglycan fragments (55). This recognition triggers MyD88/NF-κB-dependent cytokine production, including IL-1β, TNF-α and CXCL1, which facilitates neutrophil recruitment and adaptive immune activation via MHC-II and co-stimulatory molecules (CD80/86). Microglia further contribute to host defense through phagolysosomal degradation and antimicrobial peptide secretion, particularly cathelicidin LL-37 (55). However, excessive activation leads to neurotoxic effects including glutamate excitotoxicity and reactive oxygen species overproduction. Concurrently, astrocytes and pericytes modulate the inflammatory milieu and blood-brain barrier integrity. Astrocytes regulate ion/water homeostasis through aquaporin-4 channels while secreting pro-inflammatory cytokines, specifically interleukin-6 and CCL2, following Toll-like receptor activation (56, 57). Pericytes respond to bacterial toxins by altering PDGFR-β/TGF-β signaling pathways, resulting in basement membrane remodeling and increased endothelial permeability (58). This integrated neurovascular response demonstrates a delicate balance between protective immunity and pathological neuroinflammation, where microglial activation states, astrocytic responses, and pericyte-mediated vascular changes collectively determine disease progression and clinical outcomes in pneumococcal meningitis (55, 58, 59).
2.3.3 Spatiotemporal regulation of neuroinflammation in pneumococcal meningitis
During pneumococcal meningitis, pattern recognition receptors (PRRs) initiate spatially and temporally regulated immune cascades. TLR2 recognizes bacterial peptidoglycan/lipoteichoic acid, TLR4-MD2 detects the β-sheet domain of pneumolysin, and endosomal TLR9 senses CpG-rich DNA via MyD88-dependent signaling, contingent on pathogen internalization (60–62). These PRRs activate NF-κB/MAPK pathways, triggering IL-6, TNF-α, and CXCL8 release, while simultaneously assembling the NLRP3 inflammasome complex (NLRP3, ASC, caspase-1), which cleaves pro-IL-1β and pro-IL-18 into active cytokines. IL-1β propagates neuroinflammation via positive feedback, and IL-18 enhances IFN-γ via STAT1–IRF1 signaling, exacerbating Th1-driven immunopathology and oxidative stress (63). PRR hyperactivation also induces release of mitochondrial DAMPs (mtDNA), fueling a self-amplifying cycle of tissue damage and secondary immune activation that promotes BBB breakdown and neuronal injury (60, 63). PRR-mediated microglial activation triggers a neurovascular cascade, where endothelial IL-6/TNF-α signaling via JNK/AP-1 and astrocytic IL-1β via NF-κB drive pro-inflammatory microenvironments (64, 65). CXCL12/CXCR4 arrests leukocytes at the BBB, while CCL2/CCR2 and CXCL1/CXCR2 facilitate monocyte/neutrophil transmigration (66). Neutrophils contribute to bacterial clearance through NETosis and α-defensin secretion but also inflict tissue damage via ROS and elastase-mediated ECM degradation (67, 68). Knockout models underscore dual roles: neutrophil depletion attenuates inflammation yet elevates bacterial burden, revealing compartment-specific functions (68). Infiltrating leukocytes amplify inflammation via IL-1β/caspase-1 pyroptosis, TNF-α/NF-κB-induced CAM expression, and IFN-γ/STAT1/IRF1-mediated CXCL10 production, driving Th1 polarization (69–71). Cytokine networks show nonlinearity. For instance, IL-6 knockout reduces edema but increases mortality, while IL-1R deficiency weakens the BBB yet enhances bacterial clearance, emphasizing the need for spatiotemporally balanced immunomodulation in therapy (72, 73).
2.3.4 Reactive oxygen and nitrogen species
Reactive oxygen/nitrogen species (RONS) drive neuroinflammation in pneumococcal meningitis through three axes: pathogen-driven S. pneumoniae autolysis releases H2O2, which reacts with NO· to form peroxynitrite (ONOO-), inducing lipid peroxidation and mitochondrial DNA damage; enzymatic neutrophil myeloperoxidase (MPO) generates HOCl from H2O2/Cl-, activating MMP-9 to degrade collagen IV and disrupt BBB integrity; and metabolic IFN-γ-induced NOS2 sustains NO·, which reacts with O2- to form ONOO-, nitrating occludin/ZO-1 and destabilizing tight junctions. CSF nitrate/nitrite levels correlate with BBB damage severity (74–76). RONS exhibit duality: endothelial NOS1 (eNOS) maintains microvascular integrity via PI3K/Akt, while NOS2 knockout reduces edema and cytokines, underscoring spatiotemporal specificity (77). Combined catalase/SOD therapy reduces CSF leukocytes by 50% and suppresses caspase-3-dependent apoptosis, supporting RONS-targeted strategies (75–77).
3 Streptococcal breach of the blood-brain barrier
Streptococcal pathogens invade the BBB via surface adhesins binding endothelial receptors PECAM-1 and laminin receptor, degrading tight junction proteins occludin and claudin-5, and activating MMP-2/9 to hydrolyze collagen IV, enabling transendothelial migration (78). Post-invasion, PAMPs activate NLRP3 inflammasomes via TLR2/4-NF-κB, driving caspase-1-dependent IL-1β/IL-18 release and generating reactive species (O2-, ONOO-), perpetuating a pathogen-inflammation-injury cycle (79). S. pneumoniae upregulates NLRP3/ASC via STAT6-SPDEF during nasopharyngeal colonization, while sialylated serotype-specific capsules enhance CNS penetration (80–82). S. suis serotype 2 secretes suilysin to induce endothelial pyroptosis and modulates BBB-penetrating genes (srtA, fbps) via VirR/VirS two-component signaling (83, 84). S. equi subsp. zooepidemicus and group B Streptococcus exploit adhesins and surface proteins for transcytosis, highlighting conserved yet diverse neuroinvasive strategies.
3.1 Disruption of tight junction proteins
The BBB tight junctions (TJs), composed of ZO-1/2, claudin-5, occludin, and JAMs, maintain CNS homeostasis via a high-resistance paracellular barrier (85). Streptococci disrupt TJs through oxidative stress, Streptococcus pneumoniae H2O2 is converted by myeloperoxidase (MPO) to HOCl, activating MMP-9 to degrade occludin and claudin-5, enzymatic cleavage, S. suis Stk kinase ubiquitinates claudin-5 via SMURF1, enhancing proteasomal degradation, and epigenetic regulation, group B Streptococcus suppresses TJ transcription via NF-κB/Snail1, redistributing ZO-1 and claudin-5 (74, 75, 86–91). S. pneumoniae infection elevates CSF MMP-8/9, while MMP inhibitors reduce BBB permeability (86, 87). Stk knockout (Δstk) reduces microvascular adhesion by 80% and impairs RhoA/ROCK-driven cytoskeletal contraction, confirming its dual role in TJ disruption (88, 89). Therapeutic strategies including claudin-5-stabilizing peptides and ROCK inhibitors restore BBB resistance, highlighting their translational potential (90, 91).
3.2 Activation of immune responses
The CNS innate immune system responds to streptococcal invasion of the BBB through the recognition of lipoteichoic acid (LTA) and pneumolysin (Ply) by TLR2/4 recognition of LTA/Ply, activating MyD88/NF-κB to drive IL-1β/TNF-α/CXCL8 crosstalk. In parallel, activation of the NLRP3 inflammasome complex comprising ASC and caspase-1 is triggered by potassium efflux and reactive oxygen species, resulting in IL-18 secretion and pyroptotic cell death (43). Additionally, endothelial expression of adhesion molecules ICAM-1 and VCAM-1 is upregulated, promoting neutrophil transmigration via integrin αMβ2; the extent of leukocyte infiltration positively correlates with CSF levels of matrix metalloproteinase-9 (MMP-9) (92). However, immune hyperactivation exacerbates injury: neutrophil elastase disrupts ZO-1 via PAR1/RhoA; microglial ONOO- induces mitochondrial DNA damage; and IL-1β/IL-18-STAT3/NF-κB crosstalk triples BBB permeability, triggering hippocampal caspase-3 apoptosis (92). Astrocytes worsen neuroinflammation via glutamate-glutamine excitotoxicity and macrophage M1 polarization, highlighting the need for balanced immune modulation (92). Streptococcus pneumoniae induces CNS inflammation through TLR2-MyD88-dependent microglial NF-κB activation by peptidoglycan/teichoic acid, and C1q-MBL-mediated complement activation by capsular polysaccharides, forming MACs that lyse neurons (60, 93–95). These processes elevate IL-6, TNF-α, and IL-1β in endothelia/glia. While caspase-1 knockout preserves BBB integrity by reducing IL-1β, IL-1R deficiency exacerbates leakage via compensatory TLR4-TRIF signaling (69, 70, 96–98). S. pneumoniae further recruit neutrophils through NanA-induced CXCL8/CXCR2 activation, correlating with CSF bacterial load (99). Other Streptococcus suis induces IL-1β via MyD88/TLR2-AIM2, while small RNA rss04 stabilizes TLR4 by inhibiting TRIM32 ubiquitination, reducing occludin phosphorylation (100–103). In S. equi subsp. zooepidemicus, triggers NLRP3/caspase-1 via K+ efflux, with miR-223-3p suppressing NLRP3-dependent IL-18 (104). Chemokine remodeling during pneumococcal infection drives neutrophil (CXCR1/2) and monocyte (CCR2/5) recruitment (105). NLRP6 knockout paradoxically improves survival despite increasing NETs, implicating gasdermin D in regulation (106, 107). Critical for therapeutic development, IL-1β maturation is controlled by both AIM2/NLRP3 inflammasomes and neutrophil proteases (108, 109), highlighting key targets to modulate neuroinflammation in streptococcal infections (Figure 1).
Figure 1. Molecular mechanisms of streptococcal disruption of the blood-brain barrier.
3.3 Synergistic invasion strategies of cytolytic toxins and metabolic enzymes
Streptococcal pathogens breach the BBB via membrane-targeting virulence factors: Streptococcus suis suilysin (Sly) forms 30–50 nm pores in endothelial membranes, inducing Ca²+-dependent calpain activation and an increase in phospholipase A2 (PLA2G3) activity, which hydrolyzes lipids to disrupt barrier integrity. Wild-type sly strains exhibit higher BBB penetration than mutants (84, 110). Streptococcus pneumoniae pneumolysin triggers p38 MAPK/NFATc1 signaling via pre-pore complexes, upregulating IL-1α and reducing endothelial resistance. Sublytic Ply inhibits autophagy via PI3K/Akt/mTOR, inducing mitochondrial collapse and caspase-9-dependent apoptosis (51, 111, 112). S. suis enolase (Eno) binds ribosomal protein RPSA, activating p38/ERK-eIF4E to elevate HSPD1 and induce cytoskeletal rearrangements, forming intercellular gaps. Eno also stimulates TLR4/MyD88-dependent IL-8 secretion, exacerbating edema and enhancing BBB penetration (113–115). These findings reveal Streptococcus employs synergistic toxin-enzyme strategies, offering novel therapeutic targets (51, 110–115) (Table 1).
Table 1. Molecular mechanisms of streptococcal BBB disruption.
4 Molecular mechanisms of immune dysregulation and neural injury
Following Streptococcus pneumoniae breach of the BBB, capsular polysaccharides mediate immune evasion via C3b/iC3b complement inhibition and resisting neutrophil extracellular trap (NET) adhesion, while simultaneously activating microglial TLR4/MyD88 signaling to drive excessive IL-6, IL-1β, and TNF-α, establishing a pro-inflammatory cascade (116–118). This response precipitates oxidative stress and cytokine storms, leading to mitochondrial DNA damage and caspase-3–dependent neuronal apoptosis in the hippocampus—pathologies strongly correlated with long-term cognitive deficits in meningitis survivors (119, 120). Notably, N-acetylcysteine (NAC) reduces BBB permeability and restores cognitive function scores by inhibiting NF-κB nuclear translocation, whereas doxycycline improve long-term neurological outcomes by preventing MMP-9-mediated ZO-1 degradation (120).
Streptococcus pneumoniae exhibits spatiotemporal virulence heterogeneity: high-pneumolysin (Ply) strains activate ATG5/LC3-II–mediated autophagy and enable bacterial clearance via p62/SQSTM1, whereas low-Ply strains inhibit autophagosome maturation and show 2.3-fold higher BBB penetration (121, 122). Similarly, Streptococcus suis Sly forms 25–30 nm pores to activate NLRP3 inflammasomes, increasing IL-18 secretion fivefold, an effect reversible by cryptotanshinone through Sly oligomerization blockade (123, 124). Additionally, S. suis also upregulates ATG7/Beclin1 via IFN-γ/STAT1, inducing aberrant autophagy in brain endothelia and reducing occludin phosphorylation (125). Group B Streptococcus employs complementary evasion strategies, including sialylated capsule-mediated complement resistance and PilA-triggered CXCL8 secretion via α2β1 integrin-FAK signaling, which enhances neutrophil transmigration (126–129). The CovR/CiaR regulatory system further modulates invasion by suppressing capsular gene cpsE, tripling BBB penetration in serotype III strains, though CovR phosphorylation inhibitors restore barrier integrity (127, 128). Streptococci thus subvert BBB defense through C3 convertase inhibition, autophagy suppression, and immunosuppressive IL-10/TGF-β upregulation. To overcome therapeutic delivery barriers, LDL receptor–targeting lipoprotein-mimetic β-lactamase inhibitors offer a promising nanodelivery strategy for CNS infections (117, 118, 121, 122).
5 Conclusion
The molecular interplay between streptococcal virulence factors and BBB defenses underscores the complexity of bacterial meningitis pathogenesis. Key mechanisms, ranging from adhesion mediated tight junction degradation and toxin driven endothelial pyroptosis to reactive oxygen and nitrogen species cytokine crosstalk, highlight the pathogen’s ability to exploit host inflammatory responses for central nervous system invasion. Paradoxically, excessive immune activation exacerbates neural injury, emphasizing the need for balanced immunomodulation. While current therapies remain limited by BBB impermeability and antibiotic resistance, advances in nanotechnology such as LDLR targeted drug delivery and virulence factor inhibitors like cryptotanshinone against SLY present novel avenues for intervention. Future research must prioritize spatiotemporal mapping of pathogen host interactions, particularly the roles of microglial polarization and meningeal lymphatic drainage in disease progression. A multidisciplinary approach integrating pathogen specific strategies and BBB preservation is essential to reduce the global burden of meningitis related morbidity and mortality.
Author contributions
YS: Writing – original draft. TL: Writing – review & editing. CS: Writing – review & editing. BY: Writing – review & editing. BX: Writing – review & editing. JZ: Writing – review & editing, Supervision, Formal Analysis.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by National Natural Science Foundation of China (81760225), Guizhou Provincial Health Commission Science and Technology Fund for 2024, gzwkj2024-086.
Conflict of interest
The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Venkatareddy MP, Upadhya D, Yegneswaran PP, Varghese A, Pahadasingh S, Prabhu AN, et al. Molecular diagnostic methods for rapid diagnosis of central nervous system infections. Front Med Technol. (2025) 7:1497512. doi: 10.3389/fmedt.2025.1497512
2. Gil E, Wall E, Noursadeghi M, and Brown JS. Streptococcus pneumoniae meningitis and the CNS barriers. Front Cell Infect Microbiol. (2022) 12:1106596. doi: 10.3389/fcimb.2022.1106596
3. Yang R, Wang J, Wang F, Zhang H, Tan C, Chen H, et al. Blood-brain barrier integrity damage in bacterial meningitis: the underlying link, mechanisms, and therapeutic targets. Int J Mol Sci. (2023) 24:2852. doi: 10.3390/ijms24032852
4. Alexander NG, Cutts WD, Hooven TA, and Kim BJ. Mechanisms and manifestations of group B streptococcus meningitis in newborns. J Pediatr Infect Dis Soc. (2025) 14:103. doi: 10.1093/jpids/piae103
5. Ibrahim A, Saleem N, Naseer F, Ahmed S, Munawar N, and Nawaz R. From cytokines to chemokines: Understanding inflammatory signaling in bacterial meningitis. Mol Immunol. (2024) 173:117–26. doi: 10.1016/j.molimm.2024.07.004
6. Xu H, Lotfy P, Gelb S, Pragana A, Hehnly C, Byer LIJ, et al. The choroid plexus synergizes with immune cells during neuroinflammation. Cell. (2024) 187:4946–4963.e4917. doi: 10.1016/j.cell.2024.07.002
7. Elmi-Terander A, El-Hajj VG, and Edström E. Intracranial pressure monitoring in the management of acute bacterial meningitis: controversy or clinical practice? Acta Neurochir (Wien). (2024) 166:322. doi: 10.1007/s00701-024-06205-9
8. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, and Hughes JM. Meningococcal disease. N Engl J Med. (2001) 344:1378–88. doi: 10.1056/NEJM200105033441807
9. Petersdorf RG, Swarner DR, and Garcia M. Studies on the pathogenesis of meningitis. II. Development of meningitis during pneumococcal bacteremia. J Clin Invest. (1962) 41:320–7. doi: 10.1172/JCI104485
10. Hasbun R. Progress and challenges in bacterial meningitis: A review. Jama. (2022) 328:2147–54. doi: 10.1001/jama.2022.20521
11. Koedel U, Scheld WM, and Pfister HW. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis. (2002) 2:721–36. doi: 10.1016/S1473-3099(02)00450-4
12. Zainel A, Mitchell H, and Sadarangani M. Bacterial meningitis in children: neurological complications, associated risk factors, and prevention. Microorganisms. (2021) 9:535. doi: 10.3390/microorganisms9030535
13. Wei C, Jiang W, Wang R, Zhong H, He H, Gao X, et al. Brain endothelial GSDMD activation mediates inflammatory BBB breakdown. Nature. (2024) 629:893–900. doi: 10.1038/s41586-024-07314-2
14. Porkoláb G, Mészáros M, Szecskó A, Vigh JP, Walter FR, Figueiredo R, et al. Synergistic induction of blood-brain barrier properties. Proc Natl Acad Sci U.S.A. (2024) 121:e2316006121. doi: 10.1073/pnas.2316006121
15. Zheng X, Ren B, and Gao Y. Tight junction proteins related to blood-brain barrier and their regulatory signaling pathways in ischemic stroke. BioMed Pharmacother. (2023) 165:115272. doi: 10.1016/j.biopha.2023.115272
16. Zhao Y, Gan L, Ren L, Lin Y, Ma C, and Lin X. Factors influencing the blood-brain barrier permeability. Brain Res. (2022) 1788:147937. doi: 10.1016/j.brainres.2022.147937
17. Vrillon A, Ashton NJ, Bouaziz-Amar E, Mouton-Liger F, Cognat E, Dumurgier J, et al. Dissection of blood-brain barrier dysfunction through CSF PDGFRβ and amyloid, tau, neuroinflammation, and synaptic CSF biomarkers in neurodegenerative disorders. EBioMedicine. (2025) 115:105694. doi: 10.1016/j.ebiom.2025.105694
18. Tan G, Wang J, Xing W, and He Z. The role of the PDGF-BB/PDGFR-β signaling pathway in microcirculatory disturbances and BBB destruction after experimental subarachnoid hemorrhage in mice. Microvasc Res. (2025) 160:104816. doi: 10.1016/j.mvr.2025.104816
19. Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland BA, et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. (2014) 508:55–60. doi: 10.1038/nature13165
20. Cheng J, Zheng Y, Cheng F, Wang C, Han J, Zhang H, et al. Different roles of astrocytes in the blood-brain barrier during the acute and recovery phases of stroke. Neural Regener Res. (2025) 21:1359–72. doi: 10.4103/NRR.NRR-D-24-01417
21. Streit WJ, Conde JR, Fendrick SE, Flanary BE, and Mariani CL. Role of microglia in the central nervous system’s immune response. Neurol Res. (2005) 27:685–91. doi: 10.1179/016164105X49463a
22. Fakorede S, Lateef OM, GAruba WA, Akosile PO, Okon DA, and Aborode AT. Dual impact of neuroinflammation on cognitive and motor impairments in Alzheimer’s disease. J Alzheimers Dis Rep. (2025) 9:25424823251341870. doi: 10.1177/25424823251341870
23. Ayasoufi K, Wolf DM, Namen SL, Jin F, Tritz ZP, Pfaller CK, et al. Brain resident memory T cells rapidly expand and initiate neuroinflammatory responses following CNS viral infection. Brain Behav Immun. (2023) 112:51–76. doi: 10.1016/j.bbi.2023.05.009
24. Nakajima A, Yanagimura F, Saji E, Shimizu H, Toyoshima Y, Yanagawa K, et al. Stage-dependent immunity orchestrates AQP4 antibody-guided NMOSD pathology: a role for netting neutrophils with resident memory T cells. situ. Acta Neuropathol. (2024) 147:76. doi: 10.1007/s00401-024-02725-x
25. Zhao Z, Nelson AR, Betsholtz C, and Zlokovic BV. Establishment and dysfunction of the blood-brain barrier. Cell. (2015) 163:1064–78. doi: 10.1016/j.cell.2015.10.067
26. Hudson LC, Bragg DC, Tompkins MB, and Meeker RB. Astrocytes and microglia differentially regulate trafficking of lymphocyte subsets across brain endothelial cells. Brain Res. (2005) 1058:148–60. doi: 10.1016/j.brainres.2005.07.071
27. Araujo AP, Oliveira MLS, and Miyaji EN. Negligible role for pneumococcal surface protein A (PspA) and pneumococcal surface protein C (PspC) in the nasopharyngeal colonization of mice with a serotype 6B pneumococcal strain. Microb Pathog. (2023) 185:106391. doi: 10.1016/j.micpath.2023.106391
28. Adler H, German EL, Mitsi E, Nikolaou E, Pojar S, Hales C, et al. : experimental human pneumococcal colonization in older adults is feasible and safe, not immunogenic. Am J Respir Crit Care Med. (2021) 203:604–13. doi: 10.1164/rccm.202004-1483OC
29. Brooks LRK and Mias GI. Streptococcus pneumoniae’s virulence and host immunity: aging, diagnostics, and prevention. Front Immunol. (2018) 9:1366. doi: 10.3389/fimmu.2018.01366
30. Gingerich AD and Mousa JJ. Diverse mechanisms of protective anti-pneumococcal antibodies. Front Cell Infect Microbiol. (2022) 12:824788. doi: 10.3389/fcimb.2022.824788
31. Middleton DR, Paschall AV, Duke JA, and Avci FY. Enzymatic hydrolysis of pneumococcal capsular polysaccharide renders the bacterium vulnerable to host defense. Infect Immun. (2018) 86:e00316. doi: 10.1128/IAI.00316-18
32. Agnew HN, Atack JM, Fernando ARD, Waters SN, van der Linden M, Smith E, et al. Uncovering the link between the SpnIII restriction modification system and LuxS in Streptococcus pneumoniae meningitis isolates. Front Cell Infect Microbiol. (2023) 13:1177857. doi: 10.3389/fcimb.2023.1177857
33. Laczkovich I, Mangano K, Shao X, Hockenberry AJ, Gao Y, Mankin A, et al. Discovery of unannotated small open reading frames in streptococcus pneumoniae D39 involved in quorum sensing and virulence using ribosome profiling. mBio. (2022) 13:e0124722. doi: 10.1128/mbio.01247-22
34. Iovino F, Engelen-Lee JY, Brouwer M, van de Beek D, van der Ende A, Valls Seron M, et al. pIgR and PECAM-1 bind to pneumococcal adhesins RrgA and PspC mediating bacterial brain invasion. J Exp Med. (2017) 214:1619–30. doi: 10.1084/jem.20161668
35. Sharapova Y, Suplatov D, and Švedas V. Neuraminidase A from Streptococcus pneumoniae has a modular organization of catalytic and lectin domains separated by a flexible linker. FEBS J. (2018) 285:2428–45. doi: 10.1111/febs.14486
36. Alghofaili F, Najmuldeen H, Kareem BO, Shlla B, Fernandes VE, Danielsen M, et al. Host stress signals stimulate pneumococcal transition from colonization to dissemination into the lungs. mBio. (2021) 12:e0256921. doi: 10.1128/mBio.02569-21
37. Cremers AJH, Mobegi FM, van der Gaast-de Jongh C, van Weert M, van Opzeeland FJ, Vehkala M, et al. The contribution of genetic variation of streptococcus pneumoniae to the clinical manifestation of invasive pneumococcal disease. Clin Infect Dis. (2019) 68:61–9. doi: 10.1093/cid/ciy417
38. Takahara Y, Sumitomo T, Kono M, Takemura M, Akamatsu Y, Hirose Y, et al. Pneumolysin contributes to dysfunction of nasal epithelial barrier for promotion of pneumococcal dissemination into brain tissue. mSphere. (2024) 9:e0065524. doi: 10.1128/msphere.00655-24
39. Shen K, Miao W, Zhu L, Hu Q, Ren F, Dong X, et al. A 3’UTR-derived small RNA represses pneumolysin synthesis and facilitates pneumococcal brain invasion. Commun Biol. (2024) 7:1130. doi: 10.1038/s42003-024-06845-8
40. van Pee K, Neuhaus A, D’Imprima E, Mills DJ, Kühlbrandt W, and Yildiz Ö. CryoEM structures of membrane pore and prepore complex reveal cytolytic mechanism of Pneumolysin. Elife. (2017) 6:e23644. doi: 10.7554/eLife.23644
41. Lokken-Toyli KL, Aggarwal SD, Bee GCW, de Steenhuijsen Piters WAA, Wu C, Chen KZM, et al. Impaired upper respiratory tract barrier function during postnatal development predisposes to invasive pneumococcal disease. PloS Pathog. (2024) 20:e1012111. doi: 10.1371/journal.ppat.1012111
42. Jacques LC, Panagiotou S, Baltazar M, Senghore M, Khandaker S, Xu R, et al. Increased pathogenicity of pneumococcal serotype 1 is driven by rapid autolysis and release of pneumolysin. Nat Commun. (2020) 11:1892. doi: 10.1038/s41467-020-15751-6
43. Kim JY, Paton JC, Briles DE, Rhee DK, and Pyo S. Streptococcus pneumoniae induces pyroptosis through the regulation of autophagy in murine microglia. Oncotarget. (2015) 6:44161–78. doi: 10.18632/oncotarget.6592
44. Pereira JM, Xu S, Leong JM, and Sousa S. The yin and yang of pneumolysin during pneumococcal infection. Front Immunol. (2022) 13:878244. doi: 10.3389/fimmu.2022.878244
45. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, Thompson CM, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U.S.A. (2003) 100:1966–71. doi: 10.1073/pnas.0435928100
46. Matsuyama S, Komatsu K, Lee BC, Tasaki Y, Miyata M, Xu H, et al. Negative cross-talk between TLR2/4-independent AMPKα1 and TLR2/4-dependent JNK regulates S. pneumoniae-induced mucosal innate immune response. J Immunol. (2022) 209:1532–44. doi: 10.4049/jimmunol.2100901
47. Braun JS, Hoffmann O, Schickhaus M, Freyer D, Dagand E, Bermpohl D, et al. Pneumolysin causes neuronal cell death through mitochondrial damage. Infect Immun. (2007) 75:4245–54. doi: 10.1128/IAI.00031-07
48. Nerlich A, Mieth M, Letsiou E, Fatykhova D, Zscheppang K, Imai-Matsushima A, et al. Pneumolysin induced mitochondrial dysfunction leads to release of mitochondrial DNA. Sci Rep. (2018) 8:182. doi: 10.1038/s41598-017-18468-7
49. Nerlich A, von Wunsch Teruel I, Mieth M, Hönzke K, Rückert JC, Mitchell TJ, et al. Reversion of pneumolysin-induced executioner caspase activation redirects cells to survival. J Infect Dis. (2021) 223:1973–83. doi: 10.1093/infdis/jiaa639
50. Yang R, Wang J, Wang F, Zhang H, Tan C, Chen H, et al. : Blood–brain barrier integrity damage in bacterial meningitis: the underlying link, mechanisms, and therapeutic targets. Int J Mol Sci. (2023) 24:2852. doi: 10.3390/ijms24032852
51. Zysk G, Schneider-Wald BK, Hwang JH, Bejo L, Kim KS, Mitchell TJ, et al. Pneumolysin is the main inducer of cytotoxicity to brain microvascular endothelial cells caused by Streptococcus pneumoniae. Infect Immun. (2001) 69:845–52. doi: 10.1128/IAI.69.2.845-852.2001
52. Doran KS, Fulde M, Gratz N, Kim BJ, Nau R, Prasadarao N, et al. Host-pathogen interactions in bacterial meningitis. Acta Neuropathol. (2016) 131:185–209. doi: 10.1007/s00401-015-1531-z
53. Pramitasuri TI, Susilawathi NM, Tarini NMA, Sudewi AR, and Evans MC. Cholesterol dependent cytolysins and the brain: Revealing a potential therapeutic avenue for bacterial meningitis. AIMS Microbiol. (2023) 9:647–67. doi: 10.3934/microbiol.2023033
54. Geldhoff M, Mook-Kanamori BB, Brouwer MC, Troost D, Leemans JC, Flavell RA, et al. Inflammasome activation mediates inflammation and outcome in humans and mice with pneumococcal meningitis. BMC Infect Dis. (2013) 13:358. doi: 10.1186/1471-2334-13-358
55. Brandenburg LO, Varoga D, Nicolaeva N, Leib SL, Wilms H, Podschun R, et al. Role of glial cells in the functional expression of LL-37/rat cathelin-related antimicrobial peptide in meningitis. J Neuropathol Exp Neurol. (2008) 67:1041–54. doi: 10.1097/NEN.0b013e31818b4801
56. Sun L, Li M, Ma X, Feng H, Song J, Lv C, et al. Inhibition of HMGB1 reduces rat spinal cord astrocytic swelling and AQP4 expression after oxygen-glucose deprivation and reoxygenation via TLR4 and NF-κB signaling in an IL-6-dependent manner. J Neuroinflamm. (2017) 14:231. doi: 10.1186/s12974-017-1008-1
57. Zhou Z, Zhan J, Cai Q, Xu F, Chai R, Lam K, et al. The water transport system in astrocytes-aquaporins. Cells. (2022) 11:e3. doi: 10.3390/cells11162564
58. Teske NC, Dyckhoff-Shen S, Beckenbauer P, Bewersdorf JP, Engelen-Lee JY, Hammerschmidt S, et al. Pericytes are protective in experimental pneumococcal meningitis through regulating leukocyte infiltration and blood-brain barrier function. J Neuroinflamm. (2023) 20:267. doi: 10.1186/s12974-023-02938-z
59. Almutairi MM, Gong C, Xu YG, Chang Y, and Shi H. Factors controlling permeability of the blood-brain barrier. Cell Mol Life Sci. (2016) 73:57–77. doi: 10.1007/s00018-015-2050-8
60. Tomlinson G, Chimalapati S, Pollard T, Lapp T, Cohen J, Camberlein E, et al. TLR-mediated inflammatory responses to Streptococcus pneumoniae are highly dependent on surface expression of bacterial lipoproteins. J Immunol. (2014) 193:3736–45. doi: 10.4049/jimmunol.1401413
61. Dyckhoff-Shen S, Masouris I, Islam H, Hammerschmidt S, Angele B, Marathe V, et al. Combining antibiotic with anti-TLR2/TLR13 therapy prevents brain pathology in pneumococcal meningitis. JCI Insight. (2024) 9:2564. doi: 10.1172/jci.insight.165737
62. Koedel U, Klein M, and Pfister HW. New understandings on the pathophysiology of bacterial meningitis. Curr Opin Infect Dis. (2010) 23:217–23. doi: 10.1097/QCO.0b013e328337f49e
63. Sollberger G, Strittmatter GE, Garstkiewicz M, Sand J, and Beer HD. Caspase-1: the inflammasome and beyond. Innate Immun. (2014) 20:115–25. doi: 10.1177/1753425913484374
64. Ferwerda B, Valls Serón M, Jongejan A, Zwinderman AH, Geldhoff M, van der Ende A, et al. Variation of 46 innate immune genes evaluated for their contribution in pneumococcal meningitis susceptibility and outcome. EBioMedicine. (2016) 10:77–84. doi: 10.1016/j.ebiom.2016.07.011
65. Kim K, Abramishvili D, Du S, Papadopoulos Z, Cao J, Herz J, et al. Meningeal lymphatics-microglia axis regulates synaptic physiology. Cell. (2025) 188:2705–2719.e2723. doi: 10.1016/j.cell.2025.02.022
66. Yang S, Edman LC, Sánchez-Alcañiz JA, Fritz N, Bonilla S, Hecht J, et al. Cxcl12/Cxcr4 signaling controls the migration and process orientation of A9-A10 dopaminergic neurons. Development. (2013) 140:4554–64. doi: 10.1242/dev.098145
67. Takeshita Y and Ransohoff RM. Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev. (2012) 248:228–39. doi: 10.1111/j.1600-065X.2012.01127.x
68. Yau B, Too LK, Ball HJ, and Hunt NH. TIGR4 strain causes more severe disease than WU2 strain in a mouse model of Streptococcus pneumoniae meningitis: a common pathogenic role for interferon-γ. Microbes Infect. (2017) 19:413–21. doi: 10.1016/j.micinf.2017.04.002
69. Yau B, Mitchell AJ, Too LK, Ball HJ, and Hunt NH. Interferon-γ-induced nitric oxide synthase-2 contributes to blood/brain barrier dysfunction and acute mortality in experimental streptococcus pneumoniae meningitis. J Interferon Cytokine Res. (2016) 36:86–99. doi: 10.1089/jir.2015.0078
70. Koedel U, Winkler F, Angele B, Fontana A, Flavell RA, and Pfister HW. Role of Caspase-1 in experimental pneumococcal meningitis: Evidence from pharmacologic Caspase inhibition and Caspase-1-deficient mice. Ann Neurol. (2002) 51:319–29. doi: 10.1002/ana.10103
71. Pettini E, Fiorino F, Cuppone AM, Iannelli F, Medaglini D, and Pozzi G. Interferon-γ from brain leukocytes enhances meningitis by type 4 streptococcus pneumoniae. Front Microbiol. (2015) 6:1340. doi: 10.3389/fmicb.2015.01340
72. Ha JY, Choi SY, Lee JH, Hong SH, and Lee HJ. Delivery of periodontopathogenic extracellular vesicles to brain monocytes and microglial IL-6 promotion by RNA cargo. Front Mol Biosci. (2020) 7:596366. doi: 10.3389/fmolb.2020.596366
73. Lai J, Jiang J, Zhang P, Xi C, Wu L, Gao X, et al. Impaired blood-brain barrier in the microbiota-gut-brain axis: Potential role of bipolar susceptibility gene TRANK1. J Cell Mol Med. (2021) 25:6463–9. doi: 10.1111/jcmm.16611
74. Barichello T, Generoso JS, Simões LR, Elias SG, and Quevedo J. Role of oxidative stress in the pathophysiology of pneumococcal meningitis. Oxid Med Cell Longev. (2013) 2013:371465. doi: 10.1155/2013/371465
75. Meli DN, Christen S, and Leib SL. Matrix metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway. J Infect Dis. (2003) 187:1411–5. doi: 10.1086/374644
76. Braun JS, Novak R, Herzog KH, Bodner SM, Cleveland JL, and Tuomanen EI. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat Med. (1999) 5:298–302. doi: 10.1038/6514
77. Li Z, Ma QQ, Yan Y, Xu FD, Zhang XY, Zhou WQ, et al. Edaravone attenuates hippocampal damage in an infant mouse model of pneumococcal meningitis by reducing HMGB1 and iNOS expression via the Nrf2/HO-1 pathway. Acta Pharmacol Sin. (2016) 37:1298–306. doi: 10.1038/aps.2016.71
78. Al-Obaidi MMJ and Desa MNM. Mechanisms of blood brain barrier disruption by different types of bacteria, and bacterial-host interactions facilitate the bacterial pathogen invading the brain. Cell Mol Neurobiol. (2018) 38:1349–68. doi: 10.1007/s10571-018-0609-2
79. Coutinho LG, Grandgirard D, Leib SL, and Agnez-Lima LF. Cerebrospinal-fluid cytokine and chemokine profile in patients with pneumococcal and meningococcal meningitis. BMC Infect Dis. (2013) 13:326. doi: 10.1186/1471-2334-13-326
80. Fang R, Uchiyama R, Sakai S, Hara H, Tsutsui H, Suda T, et al. ASC and NLRP3 maintain innate immune homeostasis in the airway through an inflammasome-independent mechanism. Mucosal Immunol. (2019) 12:1092–103. doi: 10.1038/s41385-019-0181-1
81. Weiser JN, Ferreira DM, and Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. (2018) 16:355–67. doi: 10.1038/s41579-018-0001-8
82. Iovino F, Orihuela CJ, Moorlag HE, Molema G, and Bijlsma JJ. Interactions between blood-borne Streptococcus pneumoniae and the blood-brain barrier preceding meningitis. PloS One. (2013) 8:e68408. doi: 10.1371/journal.pone.0068408
83. Gottschalk M, Segura M, and Xu J. Streptococcus suis infections in humans: the Chinese experience and the situation in North America. Anim Health Res Rev. (2007) 8:29–45. doi: 10.1017/S1466252307001247
84. Charland N, Nizet V, Rubens CE, Kim KS, Lacouture S, and Gottschalk M. Streptococcus suis serotype 2 interactions with human brain microvascular endothelial cells. Infect Immun. (2000) 68:637–43. doi: 10.1128/IAI.68.2.637-643.2000
85. Zhou Y, Peng Z, Seven ES, and Leblanc RM. Crossing the blood-brain barrier with nanoparticles. J Control Release. (2018) 270:290–303. doi: 10.1016/j.jconrel.2017.12.015
86. Leppert D, Leib SL, Grygar C, Miller KM, Schaad UB, and Holländer GA. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clin Infect Dis. (2000) 31:80–4. doi: 10.1086/313922
87. Barichello T, Generoso JS, Michelon CM, Simões LR, Elias SG, Vuolo F, et al. Inhibition of matrix metalloproteinases-2 and -9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats. Exp Biol Med (Maywood). (2014) 239:225–31. doi: 10.1177/1535370213508354
88. Rui L, Weiyi L, Yu M, Hong Z, Jiao Y, Zhe M, et al. The serine/threonine protein kinase of Streptococcus suis serotype 2 affects the ability of the pathogen to penetrate the blood-brain barrier. Cell Microbiol. (2018) 20:e12862 doi: 10.1111/cmi.12862
89. Li W, Yin Y, Meng Y, Zhou H, Ma Z, Lin H, et al. Proteomic analysis of bEnd.3 cells infected with wild-type and stk-deficient strains of Streptococcus suis serotype 2 reveals protein and pathway regulation. J Proteomics. (2021) 230:103983. doi: 10.1016/j.jprot.2020.103983
90. Lv Q, Hao H, Bi L, Zheng Y, Zhou X, and Jiang Y. Suilysin remodels the cytoskeletons of human brain microvascular endothelial cells by activating RhoA and Rac1 GTPase. Protein Cell. (2014) 5:261–4. doi: 10.1007/s13238-014-0037-0
91. Kim BJ, Hancock BM, Bermudez A, Del Cid N, Reyes E, van Sorge NM, et al. Bacterial induction of Snail1 contributes to blood-brain barrier disruption. J Clin Invest. (2015) 125:2473–83. doi: 10.1172/JCI74159
92. Selvaraj SK, Periandythevar P, and Prasadarao NV. Outer membrane protein A of Escherichia coli K1 selectively enhances the expression of intercellular adhesion molecule-1 in brain microvascular endothelial cells. Microbes Infect. (2007) 9:547–57. doi: 10.1016/j.micinf.2007.01.020
93. Nagai K, Domon H, Maekawa T, Oda M, Hiyoshi T, Tamura H, et al. Pneumococcal DNA-binding proteins released through autolysis induce the production of proinflammatory cytokines via toll-like receptor 4. Cell Immunol. (2018) 325:14–22. doi: 10.1016/j.cellimm.2018.01.006
94. Witzenrath M, Pache F, Lorenz D, Koppe U, Gutbier B, Tabeling C, et al. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J Immunol. (2011) 187:434–40. doi: 10.4049/jimmunol.1003143
95. Marriott HM, Mitchell TJ, and Dockrell DH. Pneumolysin: a double-edged sword during the host-pathogen interaction. Curr Mol Med. (2008) 8:497–509. doi: 10.2174/156652408785747924
96. Grandgirard D, Gäumann R, Coulibaly B, Dangy JP, Sie A, Junghanss T, et al. The causative pathogen determines the inflammatory profile in cerebrospinal fluid and outcome in patients with bacterial meningitis. Mediators Inflammation. (2013) 2013:312476. doi: 10.1155/2013/312476
97. Zwijnenburg PJ, van der Poll T, Florquin S, Roord JJ, and Van Furth AM. IL-1 receptor type 1 gene-deficient mice demonstrate an impaired host defense against pneumococcal meningitis. J Immunol. (2003) 170:4724–30. doi: 10.4049/jimmunol.170.9.4724
98. Mitchell AJ, Yau B, McQuillan JA, Ball HJ, Too LK, Abtin A, et al. Inflammasome-dependent IFN-γ drives pathogenesis in Streptococcus pneumoniae meningitis. J Immunol. (2012) 189:4970–80. doi: 10.4049/jimmunol.1201687
99. Banerjee A, Van Sorge NM, Sheen TR, Uchiyama S, Mitchell TJ, and Doran KS. Activation of brain endothelium by pneumococcal neuraminidase NanA promotes bacterial internalization. Cell Microbiol. (2010) 12:1576–88. doi: 10.1111/j.1462-5822.2010.01490.x
100. Domínguez-Punaro MC, Segura M, Plante MM, Lacouture S, Rivest S, and Gottschalk M. Streptococcus suis serotype 2, an important swine and human pathogen, induces strong systemic and cerebral inflammatory responses in a mouse model of infection. J Immunol. (2007) 179:1842–54. doi: 10.4049/jimmunol.179.3.1842
101. Lavagna A, Auger JP, Girardin SE, Gisch N, Segura M, and Gottschalk M. Recognition of lipoproteins by toll-like receptor 2 and DNA by the AIM2 inflammasome is responsible for production of interleukin-1β by virulent suilysin-negative streptococcus suis serotype 2. Pathogens. (2020) 9:147. doi: 10.3390/pathogens9020147
102. OuYang X, Guo J, Lv Q, Jiang H, Zheng Y, Liu P, et al. TRIM32 drives pathogenesis in streptococcal toxic shock-like syndrome and streptococcus suis meningitis by regulating innate immune responses. Infect Immun. (2020) 88:e00957. doi: 10.1128/IAI.00957-19
103. Xiao G, Tang H, Zhang S, Ren H, Dai J, Lai L, et al. Streptococcus suis small RNA rss04 contributes to the induction of meningitis by regulating capsule synthesis and by inducing biofilm formation in a mouse infection model. Vet Microbiol. (2017) 199:111–9. doi: 10.1016/j.vetmic.2016.12.034
104. Li G, Zong X, Cheng Y, Xu J, Deng J, Huang Y, et al. miR-223-3p contributes to suppressing NLRP3 inflammasome activation in Streptococcus equi ssp. zooepidemicus infection. Vet Microbiol. (2022) 269:109430. doi: 10.1016/j.vetmic.2022.109430
105. Ramesh G, MacLean AG, and Philipp MT. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflammation. (2013) 2013:480739. doi: 10.1155/2013/480739
106. Xu D, Wu X, Peng L, Chen T, Huang Q, Wang Y, et al. The critical role of NLRP6 inflammasome in streptococcus pneumoniae infection. In Vitro In Vivo. Int J Mol Sci. (2021) 22:3876. doi: 10.3390/ijms22083876
107. Tao Q, Xu D, Jia K, Cao X, Ye C, Xie S, et al. NLRP6 serves as a negative regulator of neutrophil recruitment and function during streptococcus pneumoniae infection. Front Microbiol. (2022) 13:898559. doi: 10.3389/fmicb.2022.898559
108. Feng S, Chen T, Lei G, Hou F, Jiang J, Huang Q, et al. Absent in melanoma 2 inflammasome is required for host defence against Streptococcus pneumoniae infection. Innate Immun. (2019) 25:412–9. doi: 10.1177/1753425919860252
109. Zhang T, Du H, Feng S, Wu R, Chen T, Jiang J, et al. NLRP3/ASC/Caspase-1 axis and serine protease activity are involved in neutrophil IL-1β processing during Streptococcus pneumoniae infection. Biochem Biophys Res Commun. (2019) 513:675–80. doi: 10.1016/j.bbrc.2019.04.004
110. Sui Y, Chen Y, Lv Q, Zheng Y, Kong D, Jiang H, et al. Suilyin disrupts the blood-brain barrier by activating group III secretory phospholipase A2. Life (Basel). (2022) 12:919. doi: 10.3390/life12060919
111. Fang R, Wu R, Du H, Jin M, Liu Y, Lei G, et al. Pneumolysin-dependent calpain activation and interleukin-1α Secretion in macrophages infected with streptococcus pneumoniae. Infect Immun. (2017) 85:e00201. doi: 10.1128/IAI.00201-17
112. Hupp S, Heimeroth V, Wippel C, Förtsch C, Ma J, Mitchell TJ, et al. Astrocytic tissue remodeling by the meningitis neurotoxin pneumolysin facilitates pathogen tissue penetration and produces interstitial brain edema. Glia. (2012) 60:137–46. doi: 10.1002/glia.21256
113. Liu H, Lei S, Jia L, Xia X, Sun Y, Jiang H, et al. Streptococcus suis serotype 2 enolase interaction with host brain microvascular endothelial cells and RPSA-induced apoptosis lead to loss of BBB integrity. Vet Res. (2021) 52:30. doi: 10.1186/s13567-020-00887-6
114. Wu T, Jia L, Lei S, Jiang H, Liu J, Li N, et al. Host HSPD1 translocation from mitochondria to the cytoplasm induced by streptococcus suis serovar 2 enolase mediates apoptosis and loss of blood-brain barrier integrity. Cells. (2022) 11:2071. doi: 10.3390/cells11132071
115. Sun Y, Li N, Zhang J, Liu H, Liu J, Xia X, et al. Enolase of streptococcus suis serotype 2 enhances blood-brain barrier permeability by inducing IL-8 release. Inflammation. (2016) 39:718–26. doi: 10.1007/s10753-015-0298-7
116. Wartha F, Beiter K, Albiger B, Fernebro J, Zychlinsky A, Normark S, et al. Capsule and D-alanylated lipoteichoic acids protect Streptococcus pneumoniae against neutrophil extracellular traps. Cell Microbiol. (2007) 9:1162–71. doi: 10.1111/j.1462-5822.2006.00857.x
117. van der Maten E, Westra D, van Selm S, Langereis JD, Bootsma HJ, van Opzeeland FJ, et al. Complement factor H serum levels determine resistance to pneumococcal invasive disease. J Infect Dis. (2016) 213:1820–7. doi: 10.1093/infdis/jiw029
118. Smith BL and Hostetter MK. C3 as substrate for adhesion of Streptococcus pneumoniae. J Infect Dis. (2000) 182:497–508. doi: 10.1086/315722
119. Klein RS, Garber C, and Howard N. Infectious immunity in the central nervous system and brain function. Nat Immunol. (2017) 18:132–41. doi: 10.1038/ni.3656
120. Klein M, Koedel U, Kastenbauer S, and Pfister HW. Nitrogen and oxygen molecules in meningitis-associated labyrinthitis and hearing impairment. Infection. (2008) 36:2–14. doi: 10.1007/s15010-007-7153-1
121. Surve MV, Bhutda S, Datey A, Anil A, Rawat S, Pushpakaran A, et al. Heterogeneity in pneumolysin expression governs the fate of Streptococcus pneumoniae during blood-brain barrier trafficking. PloS Pathog. (2018) 14:e1007168. doi: 10.1371/journal.ppat.1007168
122. Hirst RA, Kadioglu A, O’Callaghan C, and Andrew PW. The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin Exp Immunol. (2004) 138:195–201. doi: 10.1111/j.1365-2249.2004.02611.x
123. Takeuchi D, Akeda Y, Nakayama T, Kerdsin A, Sano Y, Kanda T, et al. The contribution of suilysin to the pathogenesis of Streptococcus suis meningitis. J Infect Dis. (2014) 209:1509–19. doi: 10.1093/infdis/jit661
124. Liu Y, Wang H, Gao J, Wen Z, and Peng L. Cryptotanshinone ameliorates the pathogenicity of Streptococcus suis by targeting suilysin and inflammation. J Appl Microbiol. (2021) 130:736–44. doi: 10.1111/jam.14810
125. Yue C, Hu C, Xiang P, Zhang S, Xiao H, Zhou W, et al. Autophagy is a defense mechanism controlling Streptococcus suis serotype 2 infection in murine microglia cells. Vet Microbiol. (2021) 258:109103. doi: 10.1016/j.vetmic.2021.109103
126. Maisey HC, Doran KS, and Nizet V. Recent advances in understanding the molecular basis of group B Streptococcus virulence. Expert Rev Mol Med. (2008) 10:e27. doi: 10.1017/S1462399408000914
127. Cumley NJ, Smith LM, Anthony M, and May RC. The CovS/CovR acid response regulator is required for intracellular survival of group B Streptococcus in macrophages. Infect Immun. (2012) 80:1650–61. doi: 10.1128/IAI.05443-11
128. Quach D, van Sorge NM, Kristian SA, Bryan JD, Shelver DW, and Doran KS. The CiaR response regulator in group B Streptococcus promotes intracellular survival and resistance to innate immune defenses. J Bacteriol. (2009) 191:2023–32. doi: 10.1128/JB.01216-08
Keywords: bacterial meningitis, blood-brain barrier, molecular pathogenesis, neuroinflammation, streptococcal pathogens
Citation: Shi Y, Liang T, Shi C, Yao B, Xiong B and Zhang J (2026) Molecular mechanisms of streptococcal disruption of the blood-brain barrier and their pathogenic role in bacterial meningitis. Front. Immunol. 16:1628503. doi: 10.3389/fimmu.2025.1628503
Received: 14 May 2025; Accepted: 04 December 2025; Revised: 27 November 2025;
Published: 07 January 2026.
Edited by:
Sunil Joshi, QuantumImmunogenix-A Third Eye Network Inc., United StatesReviewed by:
Liang Peng, Fifth Affiliated Hospital of Guangzhou Medical University, ChinaCopyright © 2026 Shi, Liang, Shi, Yao, Xiong and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jun Zhang, enl6ajg1ODZAMTYzLmNvbQ==